Lonza has announced that, following receipt of all required regulatory approvals, it has completed its acquisition of Capsugel for $5.5 billion in cash, including refinancing of existing Capsugel debt of $2 billion.
Merger and acquisition
Richard Ridinger, Lonza’s chief executive officer said in a press statement: “Lonza and Capsugel have a highly synergistic customer base and market approach, complementary business models and closely aligned corporate cultures with a strong commitment to ethics and compliance. All of these aspects will facilitate a seamless integration.”
This acquisition is in line with Lonza’s strategy to accelerate growth and deliver value by complementing its existing offerings and opening up new market opportunities in pharma and consumer healthcare and nutrition industries.
“The acquisition of Capsugel meets Lonza’s strategic and financial goals. It accelerates our healthcare continuum strategy by giving us broader exposure to the fast-growing pharma and consumer healthcare markets,” Ridinger continued. “This new integrated approach will benefit our customers, who will gain from the simplicity and efficiency of working with one company that can provide world-leading support from APIs to excipients and dosage forms.”
Under the terms of the acquisition, Capsugel’s business will continue to work with its current structure until full integration has been achieved.